TOP > 外国特許検索 > MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE

MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE NEW

外国特許コード F200010070
整理番号 5992
掲載日 2020年5月15日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP003802
国際公開番号 WO 2019151514
国際出願日 平成31年2月4日(2019.2.4)
国際公開日 令和元年8月8日(2019.8.8)
優先権データ
  • 特願2018-018622 (2018.2.5) JP
発明の名称 (英語) MONOCYTE DIFFERENTIATION INDUCER CONTAINING ALBENDAZOLE NEW
発明の概要(英語) Provided is a monocyte differentiation inducer which contains albendazole as an active ingredient.
従来技術、競合技術の概要(英語) BACKGROUND ART
In blood disease, hematopoietic stem cells is inhibited due to the branching processes in the absence of a disease, such as leukemia, aplastic anemia, cost engineer and syndrome.
Leukemia, hematopoietic stem cells (or slightly differentiated cell) to the tumor is considered to be caused by a disease. The chemotherapy treatment is basically in the cure, chemical therapy complications organ toxicity to withstand the general health and organ function needs to be sufficiently maintained because, in older patients often chemotherapy cannot be applied, if there are temporarily no no healing in a patient older not present. For such patients with fewer side effects to the new therapeutic agent is required.
Differentiation as methods of treatment for leukemia with fewer side effects known induction therapy. Differentiation induction therapy, progenitor cells remain at the state of the continued proliferation differentiation leukemia cells, a normal maturation for kill the lifetime of the white original, many anti-cancer chemotherapeutic agent or treatment of leukemia cells such as direct disruption as compared to less side effects. However, an acute promyelocytic leukemia (ATRA) all-trans retinoic acid and/or arsenic is used as a differentiation of neutrophils to the effectiveness of the therapy differentiation induction is established, other leukemia is currently effective differentiation induction therapy is not established. Further, an acute promyelocytic leukemia ATRA of the resistance is present. Leukemia in a wide variety of medical therapies to induce the differentiation of the new effective in strongly demanded.
Aplastic anemia due to some abnormality in the hematopoietic stem cell differentiation and inhibit the disease course, cost man syndrome (alias: severe congenital neutropenia) bone marrow granulocyte-cell maturation and a poor, neutrophils decrease in the group. Leukemia, aplastic anemia, hematopoietic stem cell such as the cost of man syndrome is inhibited due to the branching processes in the disease, decrease in the hematopoietic function, neutrophils and monocytes cell infection is reduced and becomes a problem. As a countermeasure of the bacterial infection in these diseases are, at present, granulocyte-colony stimulating factor (G-CSF) to induce the differentiation of neutrophils such as the agents are administered, G-CSF administration does not increase even after the neutrophils also exist. In order to improve symptoms in these diseases, to promote differentiation of hematopoietic stem cells from the blood to induce the differentiation of valid during the desired agent.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • MORITA, Ken
  • ADACHI, Souichi
  • HAGIWARA Masatoshi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close